Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:AIMT
- CUSIP: N/A
- Web: www.aimmune.com
- Market Cap: $1.09546 billion
- Outstanding Shares: 50,342,000
- 50 Day Moving Avg: $19.91
- 200 Day Moving Avg: $19.92
- 52 Week Range: $11.40 - $27.31
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.79
- P/E Growth: 0.19
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $5.26 per share
- Price / Book: 4.18
- EBIDTA: ($91,620,000.00)
- Return on Equity: -40.99%
- Return on Assets: -39.03%
- Current Ratio: 24.35%
- Quick Ratio: 24.35%
- Average Volume: 304,554 shs.
- Beta: -1.15
- Short Ratio: 14.81
Frequently Asked Questions for Aimmune Therapeutics (NASDAQ:AIMT)
What is Aimmune Therapeutics' stock symbol?
Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."
How were Aimmune Therapeutics' earnings last quarter?
Aimmune Therapeutics, Inc. (NASDAQ:AIMT) announced its quarterly earnings data on Monday, May, 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.05. View Aimmune Therapeutics' Earnings History.
When will Aimmune Therapeutics make its next earnings announcement?
Where is Aimmune Therapeutics' stock going? Where will Aimmune Therapeutics' stock price be in 2017?
4 brokers have issued 1 year price objectives for Aimmune Therapeutics' shares. Their predictions range from $30.00 to $42.00. On average, they expect Aimmune Therapeutics' stock price to reach $36.25 in the next twelve months. View Analyst Ratings for Aimmune Therapeutics.
What are analysts saying about Aimmune Therapeutics stock?
Here are some recent quotes from research analysts about Aimmune Therapeutics stock:
- 1. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (7/11/2017)
- 2. Piper Jaffray Companies analysts commented, "Today Aimmune reported 4Q16 financial results, ending the quarter with $249M in cash. We think this cash funds the company through at least YE18. By this time, we should have results from its Phase III PALISADE program in peanut allergy and we see compelling efficacy as well as safety here as the key value-creating event for AIMT shares around YE17/early '18. By YE18, we also expect a BLA filing submitted for use in kids and teens. Based on guidance of BLA timing, and assuming the full year for BLA prep, filing and review (despite the BTD status granted to AR101), we're modestly adjusting first US peds/teens sales from 2019 to 2020, resulting in a new PT of $38. Despite this change, we continue to recommend AIMT in advance of 12-month clinical progress including, importantly, PALISADE up-dosing completion around mid'17 which we see as potentially reducing clinical risk for the program." (3/15/2017)
Who are some of Aimmune Therapeutics' key competitors?
Some companies that are related to Aimmune Therapeutics include Supernus Pharmaceuticals (SUPN), Advanced Accelerator Applications S.A. (AAAP), Repligen Corporation (RGEN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Rockwell Medical (RMTI), Assembly Biosciences (ASMB), Novan (NOVN), Check-Cap (CHEK), CorMedix (CRMD), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).
Who are Aimmune Therapeutics' key executives?
Aimmune Therapeutics' management team includes the folowing people:
- Mark D. McDade, Independent Chairman of the Board
- Stephen G. Dilly M.D. Ph.D., President, Chief Executive Officer, Director
- Eric H. Bjerkholt, Chief Financial Officer
- Jeffrey H. Knapp, Chief Operating Officer
- Susan E. Barrowcliffe, Senior Vice President, General Manager of Europe
- Mary M. Rozenman, Senior Vice President - Strategy and Corporate Development
- Douglas T. Sheehy J.D., General Counsel, Secretary
- Sue Barrowcliffe, General Manager of Europe
- Daniel C. Adelman M.D., Chief Medical Officer
- Greg Behar, Independent Director
When did Aimmune Therapeutics IPO?
(AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as the underwriters for the IPO.
Who owns Aimmune Therapeutics stock?
Aimmune Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Franklin Street Advisors Inc. NC (0.02%) and Daiwa SB Investments Ltd. (0.01%). Company insiders that own Aimmune Therapeutics stock include Douglas T Sheehy, Eric Bjerkholt, Foresite Capital Fund Ii, LP, Longitude Capital Partners Ii,, Mary M Rozenman, Stephen George Dilly, Susan E Barrowcliffe and Warren L Desouza. View Institutional Ownership Trends for Aimmune Therapeutics.
Who sold Aimmune Therapeutics stock? Who is selling Aimmune Therapeutics stock?
Aimmune Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Franklin Street Advisors Inc. NC and Daiwa SB Investments Ltd.. Company insiders that have sold Aimmune Therapeutics stock in the last year include Douglas T Sheehy, Mary M Rozenman, Stephen George Dilly, Susan E Barrowcliffe and Warren L Desouza. View Insider Buying and Selling for Aimmune Therapeutics.
How do I buy Aimmune Therapeutics stock?
Shares of Aimmune Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aimmune Therapeutics' stock price today?
MarketBeat Community Rating for Aimmune Therapeutics (NASDAQ AIMT)MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Aimmune Therapeutics stock can currently be purchased for approximately $22.00.
Earnings History for Aimmune Therapeutics (NASDAQ:AIMT)Earnings History by Quarter for Aimmune Therapeutics (NASDAQ AIMT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Aimmune Therapeutics (NASDAQ:AIMT)
2017 EPS Consensus Estimate: ($2.64)
2018 EPS Consensus Estimate: ($2.22)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Aimmune Therapeutics (NASDAQ:AIMT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Aimmune Therapeutics (NASDAQ:AIMT)
Insider Ownership Percentage: 24.56%Insider Trades by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)
Institutional Ownership Percentage: 69.62%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/21/2017||Douglas T. Sheehy||Insider||Sell||7,460||$21.66||$161,583.60|| |
|7/17/2017||Mary M Rozenman||Insider||Sell||14,940||$21.44||$320,313.60|| |
|7/5/2017||Mary M Rozenman||Insider||Sell||45,060||$20.85||$939,501.00|| |
|7/3/2017||Susan E Barrowcliffe||Insider||Sell||15,000||$20.26||$303,900.00|| |
|6/23/2017||Stephen George Dilly||Insider||Sell||49,400||$20.21||$998,374.00|| |
|5/12/2017||Eric Bjerkholt||CFO||Buy||5,000||$19.84||$99,200.00|| |
|5/10/2017||Stephen George Dilly||Insider||Sell||600||$20.15||$12,090.00|| |
|4/3/2017||Warren L Desouza||CFO||Sell||15,000||$21.58||$323,700.00|| |
|3/21/2017||Warren L Desouza||CFO||Sell||10,000||$22.95||$229,500.00|| |
|11/4/2016||Mary M Rozenman||Insider||Sell||24,096||$17.60||$424,089.60|| |
|10/5/2016||Mary M Rozenman||Insider||Sell||25,000||$16.80||$420,000.00|| |
|9/8/2016||Mary M Rozenman||Insider||Sell||30,000||$16.80||$504,000.00|| |
|5/31/2016||Foresite Capital Fund Ii, L.P.||Major Shareholder||Sell||240,000||$15.23||$3,655,200.00|| |
|3/29/2016||Longitude Capital Partners Ii,||Major Shareholder||Buy||78,504||$13.87||$1,088,850.48|| |
Headline Trends for Aimmune Therapeutics (NASDAQ:AIMT)
Latest Headlines for Aimmune Therapeutics (NASDAQ:AIMT)
|Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Given "Outperform" Rating at Wedbush|
www.americanbankingnews.com - July 24 at 9:40 PM
|Aimmune Therapeutics, Inc. (AIMT) Insider Sells $161,583.60 in Stock|
www.americanbankingnews.com - July 21 at 7:31 PM
|Aimmune Banks On Food Allergies, Study Expected To Show Positive Results|
seekingalpha.com - July 20 at 2:56 AM
|Aimmune Therapeutics, Inc. (AIMT) Given Average Rating of "Buy" by Brokerages|
www.americanbankingnews.com - July 18 at 2:43 PM
|Insider Selling: Aimmune Therapeutics, Inc. (AIMT) Insider Sells 14,940 Shares of Stock|
www.americanbankingnews.com - July 17 at 7:15 PM
|-$0.64 Earnings Per Share Expected for Aimmune Therapeutics, Inc. (AIMT) This Quarter|
www.americanbankingnews.com - July 13 at 8:13 AM
|Aimmune Therapeutics, Inc. (AIMT) Downgraded to "Hold" at Zacks Investment Research|
www.americanbankingnews.com - July 11 at 9:38 PM
|AVEO Pharmaceuticals (AVEO) Worth a Look: Stock Up 14.8%|
finance.yahoo.com - July 10 at 3:27 PM
|Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Insider Susan E. Barrowcliffe Sells 15,000 Shares|
www.americanbankingnews.com - July 6 at 7:40 PM
|Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Insider Sells $939,501.00 in Stock|
www.americanbankingnews.com - July 6 at 7:22 PM
|Aimmune Therapeutics (AIMT) Reports Enrollment of 1st Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101|
www.streetinsider.com - July 5 at 4:06 PM
|Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy|
finance.yahoo.com - July 5 at 4:06 PM
|Aimmune Therapeutics (AIMT) Shares March Higher, Can It Continue?|
finance.yahoo.com - June 30 at 3:45 PM
|Aimmune Therapeutics, Inc. (AIMT) Insider Sells $998,374.00 in Stock|
www.americanbankingnews.com - June 27 at 7:29 PM
|Aimmune Therapeutics, Inc. (AIMT) Given Consensus Rating of "Buy" by Brokerages|
www.americanbankingnews.com - June 23 at 10:06 AM
|Aimmune Therapeutics (AIMT) Presents European Phase 3 PALISADE Screening Data at EAACI|
www.streetinsider.com - June 22 at 12:26 PM
|Dynavax Technologies (DVAX) Catches Eye: Stock Gains 6.6%|
finance.yahoo.com - June 21 at 4:12 PM
|Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress|
finance.yahoo.com - June 20 at 3:59 PM
|Zacks: Analysts Expect Aimmune Therapeutics Inc (AIMT) Will Announce Earnings of -$0.64 Per Share|
www.americanbankingnews.com - June 19 at 9:40 AM
|Aimmune Therapeutics, Inc. (AIMT) Upgraded by Zacks Investment Research to Buy|
www.americanbankingnews.com - June 18 at 8:56 PM
|Aimmune Therapeutics (AIMT) to Present Data on Peanut Allergy in Europe at EAACI|
www.streetinsider.com - June 15 at 5:00 PM
|Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017|
finance.yahoo.com - June 15 at 5:00 PM
|Aimmune Therapeutics, Inc. (AIMT) Lifted to "Hold" at ValuEngine|
www.americanbankingnews.com - June 13 at 4:40 PM
|Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy|
finance.yahoo.com - June 12 at 4:29 PM
|Aimmune Therapeutics Inc (AIMT) Lowered to Hold at Zacks Investment Research|
www.americanbankingnews.com - June 9 at 8:21 PM
|Clearwater project targets peanut allergies|
finance.yahoo.com - June 8 at 3:51 PM
|Aimmune Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th|
finance.yahoo.com - June 8 at 3:51 PM
|Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy|
finance.yahoo.com - June 7 at 3:32 PM
|Aimmune Therapeutics Inc (AIMT) Receives Consensus Rating of "Buy" from Analysts|
www.americanbankingnews.com - May 29 at 9:40 AM
|Aimmune Therapeutics Inc (AIMT) Stock Rating Lowered by ValuEngine|
www.americanbankingnews.com - May 27 at 3:50 PM
|Aimmune Therapeutics Inc (AIMT) Upgraded by Zacks Investment Research to "Buy"|
www.americanbankingnews.com - May 16 at 8:18 PM
|Why These Drug Stocks May Surge|
finance.yahoo.com - May 16 at 6:57 AM
|Eric Bjerkholt Acquires 5,000 Shares of Aimmune Therapeutics Inc (AIMT) Stock|
www.americanbankingnews.com - May 15 at 7:50 PM
|Insider Selling: Aimmune Therapeutics Inc (AIMT) Insider Sells 600 Shares of Stock|
www.americanbankingnews.com - May 12 at 8:48 PM
|BRIEF-Aimmune Therapeutics enrolls first patient in late-stage trial of its peanut allergy drug|
www.reuters.com - May 12 at 3:59 PM
|Wedbush Comments on Aimmune Therapeutics Inc's Q2 2017 Earnings (AIMT)|
www.americanbankingnews.com - May 12 at 10:42 AM
|Wedbush Equities Analysts Boost Earnings Estimates for Aimmune Therapeutics Inc (AIMT)|
www.americanbankingnews.com - May 11 at 3:58 PM
|Aimmune Therapeutics (AIMT) Announces Enrollment of First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101|
www.streetinsider.com - May 11 at 3:41 PM
|Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy|
finance.yahoo.com - May 11 at 3:41 PM
|Aimmune Therapeutics Inc (AIMT) Releases Earnings Results|
www.americanbankingnews.com - May 9 at 1:38 PM
|Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16|
finance.yahoo.com - May 9 at 9:23 AM
|Aimmune Therapeutics Announces First Quarter 2017 Financial Results|
finance.yahoo.com - May 8 at 8:24 PM
|Aimmune Therapeutics reports 1Q loss|
marketbeat.com - May 8 at 4:13 PM
|Aimmune Therapeutics (AIMT) Receiving Somewhat Critical Press Coverage, AlphaOne Reports|
www.americanbankingnews.com - May 3 at 8:58 AM
|Aimmune Therapeutics Inc (AIMT) Receives Average Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - May 2 at 12:37 PM
|Biotechs Cruise On 6-Day Upswing Despite Price Target Cuts For This Duo|
finance.yahoo.com - May 1 at 3:26 PM
| Analysts Anticipate Aimmune Therapeutics Inc (AIMT) Will Announce Earnings of -$0.53 Per Share|
www.americanbankingnews.com - May 1 at 1:02 PM
|Aimmune Therapeutics (AIMT) Receives News Sentiment Score of 0.21|
www.americanbankingnews.com - April 27 at 9:34 AM
|Aimmune Therapeutics (AIMT) Earning Somewhat Favorable News Coverage, Analysis Finds|
www.americanbankingnews.com - April 24 at 12:15 PM
|Aimmune Therapeutics (AIMT) Given Media Impact Rating of -0.02|
www.americanbankingnews.com - April 21 at 9:05 AM
Aimmune Therapeutics (AIMT) Chart for Tuesday, July, 25, 2017